Latest Regulatory Approvals News

Native Mineral Resources has secured the Estimated Rehabilitation Cost decision, unlocking mining activities at the Podosky site with drilling set for January 2026 and ore processing targeted by late February.

Mount Ridley Mines has locked in nearly $1.8 million through a fully underwritten exercise of expiring unlisted options, ensuring financial backing for its Mount Ridley Project exploration and metallurgical programs.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Stellar Resources has reported a significant 51m wide tin mineralisation zone at its Severn deposit, reinforcing the potential to upgrade and expand its Heemskirk Tin Project resource. Ongoing drilling and rising tin prices underpin the company’s advancing prefeasibility study.

International Graphite Limited has secured development approval for its Collie graphite processing facility, marking a significant step toward integrated graphite production in Western Australia.

Perpetual Limited has extended its exclusivity agreement with Bain Capital into early 2026 as discussions continue over the potential sale of its Wealth Management business. While progress is steady, no binding deal is yet assured.

TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.

Pacgold has secured approval to restart heap leach irrigation at its White Dam Gold Project and is progressing a significant drilling campaign to upgrade resources, setting the stage for a production restart in 2026.

Buru Energy is actively pursuing funding for its 2026 drilling campaign to validate resources at the Rafael Gas Project, aiming for a Final Investment Decision in the second half of 2026 and first cashflow by 2028.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Equus Energy Limited launches a $15 million public offer to fund the acquisition and development of the Equus Gas Project in Western Australia, backed by conditional funding from Alcoa. The project boasts a large independently certified contingent gas resource, positioning the company to address looming supply shortfalls in domestic and LNG markets.

DEXUS has announced an estimated ordinary distribution of AUD 0.193 per unit for the six months ending December 2025, marking a steady income stream for investors ahead of the new year.